Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liprotamase versus Pancreaze in cystic fibrosis-related exocrine pancreatic insufficiency
2017-000571-85Phase 3Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Apr 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of liprotamase in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF) (2 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Change in coefficient of fat absorption. Started Apr 2017; status: terminated.
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-000571-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000571-85.